reductions in body fat have been associated with favorable shifts in inflammatory markers, potentially through changes in gene expression and mitochondrial function rather than fat distribution alone. 8 This supports the possibility that early shifts in adipose-driven inflammatory signaling, rather than reduction of visceral fat alone, may have contributed to the patient’ s improvement. Additionally, recent evidence suggests GLP-1 RAs may exert broader anti-inflammatory and cardiometabolic effects, including modulation of iNKT cell activity and reduction in vascular inflammation, which could further amplify early therapeutic benefit. 9
The 2021 American College of Rheumatology guideline for PsA emphasizes the importance of tailoring treatment to the individual, particularly in the presence of comorbid conditions such as cardiovascular disease and T2DM. 10 GLP-1 RAs may offer a promising treatment option in this population by addressing both metabolic risk and systemic inflammation through a single therapeutic class.
GLP-1 RAs have also been explored for their effects on skin physiology. A recent review by Persson et al. described potential mechanisms of action, including modulation of keratinocyte activity, microvascular function, and cutaneous immune signaling. 11 These effects have been observed across several inflammatory dermatoses, suggesting a broader dermatologic role for GLP-1 RAs that may extend beyond glycemic control. Such mechanisms could help account for the cutaneous response observed in this case.
Given the frequent overlap between PsA, obesity, and T2DM, GLP-1 RAs may represent a uniquely positioned intervention to address multiple contributors to disease activity. This case supports a collaborative approach between primary care and specialty providers to identify appropriate candidates and optimize outcomes.
CONCLUSION
A scoping review published in 2024 explored the effects of GLP-1 receptor agonists on weight management and disease activity in patients with inflammatory arthritis, including PsA. While the review identified 13 studies examining the impact of GLP-1 RAs on psoriasis, it found no studies directly reporting outcomes related to PsA. 12 Here, we present a case of a patient with persistent biopsy-confirmed PsA who experienced dramatic improvement in symptoms within two weeks of initiating therapy with a GLP- 1 receptor agonist. This case illustrates the potential of GLP-1 receptor agonists to achieve remission in persistent moderate psoriatic arthritis while concurrently improving glycemic control and promoting weight loss. These findings support further investigation of GLP-1 receptor agonists as a potential therapeutic option for patients with psoriatic arthritis, particularly those with concurrent metabolic or cardiovascular conditions.
REFERENCES
1. Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol. 2021; 12. doi: 10.3389 / fendo. 2021.721135
2. Yeo YH, Rezaie A, Hsieh TYJ, et al. Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis. Ann Intern Med. 2024; 177( 9): 1289-1291. doi: 10.7326 / M24-0019
3. Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multifaceted anti-inflammatory agent. Front Immunol. 2023; 14. doi: 10.3389 / fimmu. 2023.1148209
4. Psoriatic arthritis statistics. Verywell Health. Accessed December 21, 2024. https:// www. verywellhealth. com / psoriatic-arthritis-statistics-5196457
5. Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficult-to-treat psoriatic arthritis( D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open. 2024; 10( 1): e003809. doi: 10.1136 / rmdopen-2023-003809
6. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018; 391( 10136): 2273-2284. doi: 10.1016 / S0140-6736( 18) 30830-4
7. Zobel EH, Ripa RS, von Scholten BJ, et al. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Sci Rep. 2021; 11( 1): 18522. doi: 10.1038 / s41598-021-97967-0
8. Bianchi VE. Weight loss is a critical factor to reduce inflammation. Clin Nutr ESPEN. 2018; 28:21-35. doi: 10.1016 / j. clnesp. 2018.08.007
9. Haran K, Johnson CE, Smith P, et al. Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review. Psoriasis( Auckl). 2024; 14:143 – 152. doi: 10.2147 / PTT. S485061
10. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology / National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019; 71( 1): 5-32. doi: 10.1002 / art. 40726
11. Persson C, Eaton A, Mayrovitz HN. A closer look at the dermatological profile of GLP-1 agonists. Diseases. 2025; 13( 5): 127. doi: 10.3390 / diseases13050127
12. Karacabeyli D, Lacaille D. Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review. J Clin Rheumatol. 2024; 30( 1): 26-31. doi: 10.1097 / RHU. 0000000000001949
West Virginia Medical Journal • March 2026 • 27